Education Library

This paper discusses the latest guidance for identifying patients with cardiogenic shock (CS) who are candidates for mechanical circulatory support (MCS).

Learn more about the data and differences between part I and part II from the York data analysis.

In the presentation titled “Predictive value of residual SYNTAX score for clinical outcomes after high-risk percutaneous coronary intervention: Evidence from pooled analysis of prospective studies,” Vasileios Panoulas, MD, and colleagues...

Vasileios Panoulas, MD, discusses a pooled analysis of factors predicting outcomes at 90 days in high-risk PCI patients.

In a third-party analysis conducted by the York Health Economics Consortium was evaluated to test the hypothesis that percutaneous coronary intervention (PCI) with Impella® support...

Fadi Al-Rashid, MD, discusses his publication on standard pre-procedural clinical workup for Protected PCI.

Jürgen Leick, MD, discusses his paper on optimizing patient selection in high-risk protected percutaneous coronary intervention.

This FAQ addresses thrombus formation and anticoagulation for blood-contacting medical devices, such as the Impella® heart pump.

In this paper, Sascha Ott and colleagues describe a standard operating procedure (SOP) they developed for determining the temporary mechanical circulatory support (tMCS) strategy for patients in cardiogenic shock (CS).

Prof. Dr. med. Gregor Warnecke discusses how to achieve better outcomes in patients with postcardiotomy cardiogenic shock (PCCS).

This article presents 3 case vignettes that provide practical insights and reinforce best practices. The authors emphasize that several cardiac and patient-related factors come into play when considering patients for Protected percutaneous coronary intervention (PCI).

In this article the authors describe techniques for Impella heart pump removal with or without pre-closure and discuss how to prevent and manage complications associated with large-bore femoral access.

This article describes how the interventional cardiology team handles high-risk patients in the cath lab, from procedural preparation and planning through procedural monitoring, as well as weaning strategies and access site management.

This article explores optimal revascularization strategies for patients undergoing Protected PCI.

“The precarious balance between bleeding and thrombosis in patients with p-LVAD support is often the primary reason that patients’ outcomes are jeopardized,” write the authors of this article, which discusses anticoagulation strategies and anticoagulant management in the setting of Protected PCI.